A biomarker blood test called AlzoSure Predict that can help to identify people with mild cognitive impairment who are likely progress to Alzheimer’s disease — years before symptoms are evident — has been approved for use in the European Union (EU) and the U.K., its marketer, Diadem, announced. “This first regulatory approval for AlzoSure Predict … represents a significant advance for the millions of patients and their families in Europe at risk from Alzheimer’s disease,” Paul Kinnon, CEO of…
You must be logged in to read/download the full post.
The post Blood Test of Alzheimer’s Risk in Mild Dementia Patients OK’d in Europe appeared first on BioNewsFeeds.